

National Institute for Health & Clinical Excellence

Sickle Cell

Second Guideline Development Group (GDG) meeting
 Monday 31st October & Tuesday 1st November 2011
 Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BD

GROUP MEMBERSHIP

<u>In Attendance</u>	
GDG Members	
Damien Longson (DL) (Chair)	Brigitta Brandner
Jo Howard	Asa'ah Nkohkwo
Michele Afif	Hellen Adom
Louise Smith	Russell Keenan
Kofi Amie	Kate Ryan
Sekayi Tanganyi	Alexander McKnight (Day 2 Morning only)
NICE Staff	
Lynda Ayiku (LA)	Abitha Senthinathan (AS)
Lyn Knott (LK)	Kathryn Chamberlain (KC)
Gabriel Rogers (GR)	Mendwas Dzingina (MD)
Dylan Jones (DJ)	Mark Baker (MB)
Rachel Ryle (RR)	Victoria Gillis (VG)
Apologies:	

MINUTES OF THE MEETING

Monday 31st October 2011

1.1 Agenda item 1: Introductions, objectives, declarations of interest, minutes of the last meeting and review of GDG 1

DL welcomed the group back to the second meeting of this group. Kate and Sekayi introduced themselves to the group. DL went through the objectives for the meeting. The evidence on Non-pharmacological and adjunct therapies would be presented today. Two members declared additional interests. They were both asked to submit a new form so that these can be added to the table that will be published in the guideline.

1.2 Agenda item 2: Presentation and Discussion of the evidence of the evidence (Question 1: non-pharmacological interventions/Adjunct therapies)

AS presented the evidence on non-pharmacological interventions and adjunct therapies. 1 paper on the use of a TENS machine was included and the GDG discussed this paper and all the evidence available for this question. They discussed the quality of the evidence. The GDG discussed the use of TENS machines and felt that more research may be needed in this area.

1.3 Agenda item 3: Agree evidence statements

Having discussed the evidence the group went on to discuss and agree the evidence statements for this question.

1.4 Agenda item 4 & 5: Draft recommendations/LETR tables

The GDG made a number of recommendations relating to non-pharmacological interventions and adjunct therapies. The discussion linking the evidence to recommendations was captured and will be presented in the guideline in table format.

1.5 Agenda item 6: Health Economics – update on HE model

MD gave a presentation on the HE. He summarised the discussions from GDG 1 and the revised HE model assumptions. He then discussed the parameters in detail.

1.6 Agenda item 7: Summary of Day

DL closed the meeting.

Tuesday 1st November 2011

1.7 Agenda item 1: Review of Day 1

DL opened the meeting with a brief summary of the previous day's discussions, and discussed the plan for the day.

1.8 Agenda Item 2: Health Economics – Pharmacological interventions and Complications

GR gave an overview of the working model results: patient controlled analgesia.

- Following this the GDG discussed whether it would be helpful to have the pharmacologist attend the discussion of the evidence for the pharmacological interventions. As he has some conflicts of interest it would be appropriate for him to remain in the room during the discussion of the evidence, however it was agreed that he leave the room prior to any decisions and recommendations were made.
- Sandy introduced himself and declared his conflicts of interest. No other additional declarations of interest were received.

1.9 Agenda item 3 & 4: Evidence presented & Discussion of evidence (Q1 - Pharmacological interventions)

AS presented the evidence on the pharmacological interventions. There was a discussion about the use and inclusion of pethidine. The GDG then continued to discuss the summary and GRADE tables.

1.10 Agenda item 5, 6 & 7: Agree Evidence Statements, Draft recommendations & LETR tables

Having discussed the evidence, the GDG went on to agree the evidence statement and make a number of recommendations relating to the questions. The discussion linking the evidence to recommendations was captured and will be presented in the guideline in table format.

1.11 Agenda item 8: Research Recommendations

Throughout the discussions various themes for research had emerged. The technical team will pull these together and present them at the next meeting.

1.12 Agenda Item 9 & 10: Summary of the day/Close of meeting

KC discussed working with other teams. This would involve working with the Editors, Costing and Implementation teams. There may be a requirement to attend an editorial meeting, and possibly an implementation planning meeting. Working with the costing team usually involves the costing analyst contacting the volunteers to establish information on current practice.

Editor:

Damien Longson
Kate Ryan
Russell Keenan
Hellen Adom
Asa'ah Nkohkwo

Costings analyst:

Damien Longson
Jo Howard
Louise Smith

Implementation adviser:

Damien Longson
Michele Afif
Sekayi Tanganyi

The next meeting will be held in the NICE London office, 7th & 8th December 2011. DL closed the meeting.